Centessa Pharmaceuticals plc (CNTA) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Altrincham, United Kingdom. The current CEO is Mario Alberto Accardi.
CNTA has IPO date of 2021-05-28, 77 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $5.91B.
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company focused on discovering, developing, and delivering medicines across multiple therapeutic areas. The company's registrational pipeline includes Lixivaptan, a vasopressin V2 receptor inhibitor in Phase III development for autosomal dominant polycystic kidney disease, and SerpinPC, an activated protein C inhibitor in Phase IIa development for hemophilia A and B. Its emerging pipeline comprises innovative candidates such as LockBody immunotherapies (LB101 and LB201), ZF874 for alpha-1-antitrypsin deficiency, MGX292 for pulmonary arterial hypertension, OX2R Agonists for narcolepsy type 1, and exploratory programs including CBS001 and CBS004 targeting inflammatory and autoimmune diseases. Incorporated in 2020, Centessa is headquartered in Altrincham, United Kingdom.
